Coronary Heart Disease is the leading cause of death in our society. Underlying this disease is the pathologic process known as atherosclerosis. The central theme of this Program is to define aspects of lipoprotein metabolism important in atherogenesis. Atherosclerosis occurs when plasma low density lipoproteins (LDL) get deposited in the artery wall. Atherosclerotic lesions rich in cholesteryl esters develop in response to LDL deposition. Studies in this program project will help define how LDL precursor lipoproteins are actually made inside cells (Project by Shelness), how concentrations are controlled, and properties of LDL that make them more atherogenic. We have identified an enzyme in the liver and intestine, termed ACAT2, that appears to be important in this context, and we will use genetically engineered mice that no longer have this enzyme to show protection against atherosclerosis (Project by Rudel). We will test the hypothesis that cholesteryl oleate accumulation in plasma as LDL promotes atherosclerosis. high density lipoproteins (HDL) are the class of lipoproteins that help remove cholesterol from arteries. We will do studies to help determine how HDL particles are made. We know that the principal protein of HDL, called apoA-I, is secreted without lipid into plasma and then assembles lipid after interaction on the surface of cells with a transporter termed ABCA1. The characteristics of this interaction will be measured (Project by Parks). Further, the properties of apoA-I that determine efficient function of this apolipoprotein in lipid assimilation and transport will be assessed in Project by Sorci-Thomas. In both of these projects, genetically engineered mice will provide specific insights into molecular physiology. Finally, in Project 5, we will study the main breakdown product of cholesterol in the body, bile acids. We will examine the efficiency with which these molecules undergo enterohepatic recirculation and how this may affect plasma lipoprotein concentrations and atherosclerosis. A mouse model has been created that lacks the intestinal bile acid transporter protein that recovers the bile acids from the intestine, and this mouse will be studied to help define specific aspects of the regulation of this metabolic axis. Overall, this program project will provide basic information that will help us understand the role of lipoprotein metabolism in atherosclerosis so that prevention of CHD can be more readily achieved.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL049373-13
Application #
6901813
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Ershow, Abby
Project Start
1995-10-01
Project End
2008-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
13
Fiscal Year
2005
Total Cost
$1,798,936
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Pathology
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Schugar, Rebecca C; Shih, Diana M; Warrier, Manya et al. (2017) The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. Cell Rep 19:2451-2461
Pollard, Ricquita D; Fulp, Brian; Sorci-Thomas, Mary G et al. (2016) High-Density Lipoprotein Biogenesis: Defining the Domains Involved in Human Apolipoprotein A-I Lipidation. Biochemistry 55:4971-81
Rodríguez-Pérez, Celia; Ramprasath, Vanu Ramkumar; Pu, Shuaihua et al. (2016) Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels. Lipids 51:75-83
Warrier, Manya; Zhang, Jun; Bura, Kanwardeep et al. (2016) Sterol O-Acyltransferase 2-Driven Cholesterol Esterification Opposes Liver X Receptor-Stimulated Fecal Neutral Sterol Loss. Lipids 51:151-7
Jones, Peter J H; MacKay, Dylan S; Senanayake, Vijitha K et al. (2015) High-oleic canola oil consumption enriches LDL particle cholesteryl oleate content and reduces LDL proteoglycan binding in humans. Atherosclerosis 238:231-8
Lopez, Adam M; Chuang, Jen-Chieh; Posey, Kenneth S et al. (2015) PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient mice. J Pharmacol Exp Ther 355:159-67
Liu, Mingxia; Allegood, Jeremy; Zhu, Xuewei et al. (2015) Uncleaved ApoM signal peptide is required for formation of large ApoM/sphingosine 1-phosphate (S1P)-enriched HDL particles. J Biol Chem 290:7861-70
Melchior, John T; Olson, John D; Kelley, Kathryn L et al. (2015) Targeted Knockdown of Hepatic SOAT2 With Antisense Oligonucleotides Stabilizes Atherosclerotic Plaque in ApoB100-only LDLr-/- Mice. Arterioscler Thromb Vasc Biol 35:1920-7
Ohshiro, Taichi; Ohtawa, Masaki; Nagamitsu, Tohru et al. (2015) New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models. J Pharmacol Exp Ther 355:299-307
Marshall, Stephanie M; Kelley, Kathryn L; Davis, Matthew A et al. (2014) Reduction of VLDL secretion decreases cholesterol excretion in niemann-pick C1-like 1 hepatic transgenic mice. PLoS One 9:e84418

Showing the most recent 10 out of 242 publications